DAFNA Capital Management »

Elevation Oncology shares owned by DAFNA Capital Management

Quarter-by-quarter ownership of Elevation Oncology (ELEV) shares owned by DAFNA Capital Management from 13F filings

Historical chart of DAFNA Capital Management investment in Elevation Oncology

Tip: Access up to 7 years of quarterly data

All positions including Elevation Oncology held by DAFNA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Elevation Oncology by DAFNA Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $242k 450k 0.54
2023-09-30 $298k 450k 0.66
2023-06-30 $684k 450k 1.52

More positions owned by DAFNA Capital Management

Stereotaxis Com New (STXS)
Spdr S&p Biotech Etf Etf (XBI)
Revolution Medicines (RVMD)
Cytokinetics Com New (CYTK)
AtriCure (ATRC)
Merus N V (MRUS)
Ishares Nasdaq Biotech Indx Etf (IBB)
Ideaya Biosciences (IDYA)
Axogen (AXGN)
Xenon Pharmaceuticals (XENE)
Neurocrine Biosciences (NBIX)
Arcus Biosciences Incorporated (RCUS)
Syndax Pharmaceuticals (SNDX)
Day One Biopharmaceuticals I (DAWN)
Ascendis Pharma A/s Sponsored Adr (ASND)

View all positions for DAFNA Capital Management

Top funds holding Elevation Oncology

Advisor Group Holdings

View all funds holding Elevation Oncology